Related Experiment Video
Updated: Mar 12, 2026
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
A novel method for assaying human regulatory T cell direct suppression of B cell effector function
Elizabeth Weingartner1, Jean-Paul Courneya1, Achsah Keegan1
1Baltimore VA Medical Center, 10 N Greene St, Baltimore, MD 21201, United States; Department of Medicine, University of Maryland School of Medicine, Division of Rheumatology and Clinical Immunology, 10 S. Pine Street/MSTF Room 8-34, Baltimore, MD 21201, United States.
We developed a reliable method to test human regulatory T cells (Tregs) and their ability to suppress B cell antibody production. This protocol helps identify immune system imbalances in autoimmune diseases.
Area of Science:
- Immunology
- Cellular Biology
- Autoimmunity
Background:
- Regulatory T cells (Tregs) are crucial for immune homeostasis.
- Dysfunctional Tregs are implicated in autoimmune diseases characterized by B cell hyperactivity.
- A reliable assay for Treg-mediated suppression of B cell function is needed.
Purpose of the Study:
- To establish a reproducible protocol for assessing human Treg function.
- To quantify the suppressive capacity of Tregs on B cell IgM production.
- To provide a baseline for evaluating Tregs in autoimmune conditions.
Main Methods:
- Utilized the autoreactive Ramos B cell line as a reporter.
- Employed a straightforward IgM ELISA to measure B cell effector function.
- Tested Tregs from healthy volunteers to establish normal suppression ranges.
Main Results:
- Established a highly reproducible protocol for testing human Treg function.
- Demonstrated that Treg suppression of IgM production is contact- and death-independent.
- Quantified the variable suppressive ability of Tregs from healthy individuals.
Conclusions:
- The developed protocol reliably measures Treg-mediated suppression of B cell function.
- This assay provides a normal range for Treg suppressive capacity.
- Enables efficient testing of Tregs in autoimmune diseases with B cell hyperactivity.
